Literature DB >> 19695493

Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis.

Elisabeth Sanchez-Padilla1, Rebecca F Grais, Philippe J Guerin, Andrew D Steele, Marie-Eve Burny, Francisco J Luquero.   

Abstract

Two new rotavirus vaccines have recently been licensed in many countries. However, their efficacy has only been shown against certain serotypes commonly circulating in Europe, North America, and Latin America, but thought to be globally important. To assess the potential impact of these vaccines in sub-Saharan Africa, where rotavirus mortality is high, knowledge of prevalent types is essential because an effective rotavirus vaccine is needed to protect against prevailing serotypes in the community. We did two systematic reviews and two meta-analyses of the most recent published data on the burden of rotavirus disease in children aged under 5 years and rotavirus serotypes circulating in countries in sub-Saharan Africa. Eligible studies were selected from PubMed/Medline, Cochrane Library, EmBase, LILACS, Academic Search Premier, Biological Abstracts, ISI Web of Science, and the African Index Medicus. Depending on the heterogeneity, DerSimonian-Laird random-effects or fixed-effects models were used for meta-analyses. Geographical variability in rotavirus burden within countries in sub-Saharan Africa is substantial, and most countries lack information on rotavirus epidemiology. We estimated that annual mortality for this region was 243.3 (95% CI 187.6-301.7) deaths per 100,000 under 5 years (ie, a total of 300,000 children die of rotavirus infection in this region each year). The most common G type detected was G1 (34.9%), followed by G2 (9.1%), and G3 (8.6%). The most common P types detected were P[8] (35.5%) and P[6] (27.5%). Accurate information should be collected from surveillance based on standardised methods in these countries to obtain comparable data on the burden of disease and the circulating strains to assess the potential impact of vaccine introduction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695493     DOI: 10.1016/S1473-3099(09)70179-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  24 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  Rotavirus genotypes in Malaysia and universal rotavirus vaccination.

Authors:  Way Seah Lee; Benjamin Tze Ying Lim; Pei Fan Chai; Carl D Kirkwood; Jimmy Kok Foo Lee
Journal:  Hum Vaccin Immunother       Date:  2012-09-28       Impact factor: 3.452

3.  Whole genome analyses of G1P[8] rotavirus strains from vaccinated and non-vaccinated South African children presenting with diarrhea.

Authors:  Nonkululeko B Magagula; Mathew D Esona; Martin M Nyaga; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Mapaseka L Seheri; A Duncan Steele; David E Wentworth; M Jeffrey Mphahlele
Journal:  J Med Virol       Date:  2014-05-20       Impact factor: 2.327

Review 4.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

Review 5.  Rotavirus vaccines: update on global impact and future priorities.

Authors:  Catherine Yen; Jacqueline E Tate; Manish M Patel; Margaret M Cortese; Benjamin Lopman; Jessica Fleming; Kristen Lewis; Baoming Jiang; Jon Gentsch; Duncan Steele; Umesh D Parashar
Journal:  Hum Vaccin       Date:  2011-12-01

6.  Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.

Authors:  Nigel A Cunliffe; Desiree Witte; Bagrey M Ngwira; Stacy Todd; Nancy J Bostock; Ann M Turner; Philips Chimpeni; John C Victor; A Duncan Steele; Alain Bouckenooghe; Kathleen M Neuzil
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

7.  Rotavirus antigen, cytokine, and neutralising antibody profiles in sera of children with and without HIV infection in Blantyre, Malawi.

Authors:  Jennifer J Hull; Nigel Cunliffe; Khuzwayo C Jere; Sung-Sil Moon; Yuhuan Wang; Umesh Parashar; Baoming Jiang
Journal:  Malawi Med J       Date:  2017-03       Impact factor: 0.875

8.  Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study.

Authors:  Orbelina de Palma; Lilian Cruz; Hector Ramos; Amada de Baires; Nora Villatoro; Desiree Pastor; Lucia Helena de Oliveira; Tara Kerin; Michael Bowen; Jon Gentsch; Douglas H Esposito; Umesh Parashar; Jacqueline Tate; Manish Patel
Journal:  BMJ       Date:  2010-06-15

9.  Rotavirus G and P types circulating in the eastern region of Kenya: predominance of G9 and emergence of G12 genotypes.

Authors:  Nicholas M Kiulia; Martin M Nyaga; Mapaseka L Seheri; Marianne Wolfaardt; Walda B van Zyl; Mathew D Esona; Grace Irimu; Murithi Inoti; Bernard W Gatinu; Peter K Njenga; Maureen B Taylor; Atunga Nyachieo
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 10.  Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: is there evidence of strain selection from vaccine pressure?

Authors:  Renáta Dóró; Brigitta László; Vito Martella; Eyal Leshem; Jon Gentsch; Umesh Parashar; Krisztián Bányai
Journal:  Infect Genet Evol       Date:  2014-09-16       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.